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On behalf of the Scientific Committee, I am very pleased to welcome 
the participants of the 2nd Symposium of Young Researchers on 
Pharmaceutical Technology, Biotechnology and Regulatory Science. 
Special greetings to the young researchers who report on their PhD 
work at this event. 
The symposium series launched last year is a new initiative of the 
Institute of Pharmaceutical Technology and Regulatory Affairs, 
University of Szeged. The aim of this program was to get to know the 
work of Hungarian and international PhD students working at the 
institute, to master the basic rules of presentation and discussion. Early 
acquisition of this knowledge/skills is extremely important for mobility programs, 
conferences, publications and later for defense of theses. 
The successful 1st Symposium gave us the idea to invite our cooperative partners to 
participate in the 2nd Symposium. We are delighted to welcome 16 PhD students from Serbia, 
Romania, Czech Republic, Bosnia-Herzegovina and Slovenia. 
The Symposium provides a good opportunity to meet the cooperative partners, to discuss the 
new developments and the future directions of the pharmaceutical sciences.    
I am pleased that 70 colleagues will participate at this symposium. The program includes 1 
plenary lecture and 39 oral presentations. 
I am looking forward to having a successful conference with fruitful discussions and a nice 
time at Szeged. 
 
Prof. Piroska Szabó-Révész 
Head of Scientific Committee 
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Thursday, 23rd January 
Registration (Institute of Pharmaceutical Technology and Regulatory Affairs) 
10:00 - 11:30 Registration, visiting the institute and welcome reception 
Oral presentations (Department of Rector’s Office) 
13:00 - 14:30 Opening ceremony and plenary session 
14:30 - 15:00 Break 
15:00 - 16:45 Section 1. 
16:45 - 17:00 Break 
17:00 - 18:30 Section 2. 
19:30 - Networking event 
 
Friday, 24th January 
Oral presentations (Department of Rector’s Office) 
09:00 - 10:45 Section 3. 
10:45 - 11:00 Break 
11:00 - 12:30 Section 4. 
12:30 - 13:45 Lunch break 
13:45 - 15:30 Section 5. 
15:30 - 15:45 Break 
15:45 - 17:30 Section 6. 
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Thursday, 23rd January 
10:00-11:30 Registration and visiting the Institute (Institute of Pharmaceutical Technology and 
Regulatory Affairs, University of Szeged, 3rd floor, 6. Eötvös street, Szeged, H-6720) 
Oral Presentations (Department of Rector’s Office, University of Szeged 
13 Dugonics square, Szeged, Hungary, H-6720) 
13:00-14:30 Opening ceremony and plenary session 
14:30-15:00 Break 
15:00-16:45 Section 1. – Chairs: Prof. Dr. Edina Vranić, Dr. Géza Regdon jr.  
OP-1 – 15:00-15:15  Tivadar Bíró, Zoltán Aigner 
 In vitro and ex vivo investigation of steroid containing ocular drug 
delivery systems 
OP-2 – 15:15-15:30  Jelisaveta Ignjatović, Sandra Cvijić, Jelena Đuriš 
 Spray vs freeze-dried solid lipid microparticles: Challenges in 
 development 
OP-3 – 15:30-15:45  Péter Gieszinger, Rita Ambrus, Piroska Szabó-Révész 
 Formulation of nasal drug delivery systems to induce systemic and 
 central nervous systemic effect 
OP-4 – 15:45-16:00  Juraj Martiška, Eva Šnejdrová, Milan Dittrich 
 Formulation of medicated nanoparticles based on branched PLGA 
OP-5 – 16:00-16:15  Attila Léber, Erzsébet Csányi, Mária Budai-Szűcs 
 PLA-based nanofibrous systems for the treatment of periodontal disease 
OP-6 – 16:15-16:30  Ivana Kurcubic, Jelena Đuriš 
 Influence of experimental model, active substance and polymer type on 
 mucoadhesive properties of buccal tablets 
OP-7 – 16:30-16:45  Cristina Barbălată, Alina Porfire, Anca Cherfan, Felicia Loghin, 
 Ioan Tomuță 
 QbD development of a liposomal co-formulation with Doxorubicin and 
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17:00-18:45 Section 2. – Chair: Prof. Dr. Ioan Tomuţă, Dr. Erzsébet Csányi 
OP-8 – 17:00-17:15  Merima Sirbubalo, Amina Tucak, Edina Vranić, Andreas Zimmer 
 Stearylamine-based nanoemulsion: preparation, characterization and 
 physical stability investigation 
OP-9 – 17:15-17:30  Ruba Ismail, Ildikó Csóka 
 Potential of polymeric and Lipid based nanocarriers for oral GLP-1 
 analogue delivery 
OP-10 – 17:30-17:45  Blaž Grilc, Maja Bjelošević, Mirjana Gašperlin 
 Lactoferrin micro-encapsulation in Na-alginate hydrogel beads 
OP-11 – 17:45-18:00  Jelena Đoković, Snežana Savić 
 Curcumin loaded PEGylated nanoemulsions: development and 
 physicochemical characterization towards in vivo pharmacokinetic 
 experiments 
OP-12 – 18:00-18:15  Areen Alshweiat, IIdikó Csóka, Rita Ambrus 
 Nanosystems for improved physicochemical properties of poorly water 
 soluble loratadine 
OP-13 – 18:15-18:30  Zsófia Németh, Dorina Dobó, Edina Pallagi, Ildikó Csóka 
 Quality by Design-based approach to liposomal development 
OP-14 – 18:30-18:45  Aleksandra Gavaric, Senka Vidovic 
 Optimization of bioactive compounds of horehound extracts obtained 
 using ultrasound and microwave assisted extraction: 
 anti-hyperglycaemic activity 
 
19:30- Networking event  
Friday, 24th January 
9:00-10:45 Section 3. – Chair: Prof. Dr. Senka Vidovic, Dr. Zoltán Aigner 
OP-15 – 9:00-9:15  Krisztina Ludasi, Géza Regdon jr. 
 Development of QR coded tablets for anti-counterfeiting of drugs by 
 laser technology 
OP-16 – 9:15-9:30  Eszter L. Kiss, Erzsébet Csányi, Mária Budai-Szűcs 
 Nanostructured lipid carriers for ophthalmic use 
OP-17 – 9:30-9:45  Ana Ćirić, Ljiljana Đekić 
 Characterization of chitosan/xanthan polyelectrolyte complex carriers: 
 Influence of drug encapsulation procedure on in vitro release kinetics 
OP-18 – 9:45-10:00  Yasmin Ranjous, Géza Regdon jr., Tamás Sovány 
 The prominence of titanate nanotubes’ functionalization on their 
 physicochemical properties and biological applications as drug delivery 
 system 
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OP-19 – 10:00-10:15  Kinga Ilyés, Ioan Tomuță 
 3D-printing by fused deposition modelling in pharmaceutics 
OP-20 – 10:15-10:30  Edit Benke, Piroska Szabó-Révész, Rita Ambrus 
 Characterization of dry powder inhalation systems using an organic 
 solvent to reach special micrometric properties 
OP-21 – 10:30-10:45  Maja Bjelošević, Mirjam Gosenca Matjaž, Mirjana Gašperlin, 
 Pegi Ahlin Grabnar 
 The effect of bovine serum albumin concentration on lyophilized 
 formulation characteristics 
 
10:45-11:00 Break 
11:00-12:30 Section 4. – Chair: Prof. Dr. Mirjana Gašperlin, Dr. Tamás Sovány 
OP-22 – 11:00-11:15  Hussein Akel, Ildikó Csóka 
 Lipid based nanosystem designed for nose to brain delivery of Alzheimer 
 Disease Drug 
OP-23 – 11:15-11:30  Balázs Attila Kondoros, Zoltán Aigner 
 Physicochemical characterization and dissolution studies of terbinafine 
 hydrochloride–cyclodextrin complexes prepared by solvent-free co 
 grinding 
OP-24 – 11:30-11:45  Amina Tucak, Merima Sirbubalo, Andreas Zimmer, Edina Vranić 
 Cationic nanostructured lipid carriers (cNLCs) as drug delivery systems 
 for miRNA: investigations of formulation and process parameters 
OP-25 – 11:45-12:00  Andrea-Gabriela Crișan, Ioan Tomuță 
 Fused Deposition Modeling Three-Dimensional Printing (FDM-3DP) of 
 Channelled Tablets with Ketoprofen: Design, Development and 
 Pharmaceutical Evaluation 
OP-26 – 12:00-12:15  Ivana Vasiljević, Jelena Parojčić 
 Powder Compressibility Assessment: Manufacturability Classification 
 System vs. SeDeM Expert System 
OP-27 – 12:15-12:30  Rita Máthé, Tibor Casian, Ioan Tomuţă 
 Multivariate modelling for investigating the impact of raw materials and 
 process variability on high drug load immediate release tablets obtained 
 through wet granulation 
12:30-13:45 Lunch break 
13:45-15:30 Section 5. – Chair: Dr. Rita Ambrus, Dr. Edina Pallagi 
OP-28 – 13:45-14:00  Ernő Máté Benkő, Tamás Sovány, Ildikó Csóka 
 API – excipient interactions in solid matrix systems 
OP-29 – 14:00-14:15  Stella Zsikó, Erzsébet Csányi, Szilvia Berkó 
 Study of Skin Penetration Testing Methods 
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OP-30 – 14:15-14:30  Jelena Mitrović, Miroslav Savić, Snežana Savić 
 Nano-crystalline suspensions of novel pyrazoloquinolinones ligand 
 (DK-I 56-1): physicochemical and in vivo pharmacokinetic and 
 behavioural characterization 
OP-31 – 14:30-14:45  Patience Wobuoma, Ildikó Csóka 
 Formulation and investigations of lysozyme nanoparticle 
OP-32 – 14:45-15:00  Ines Nikolić, Snežana Savić 
 Low-energy nanoemulsions for curcumin delivery: investigation of the 
 interfacial phenomena in the colloidal system and peculiarities 
 important for biological performances 
OP-33 – 15:00-15:15  Nikolett Kis, Szilvia Berkó, Erzsébet Csányi 
 Investigation of semi-solid in situ film-forming systems with QbD 
 approach 
OP-34 – 15:15-15:30  Yousif Ibrahim, Katalin Kristó, Géza Regdon jr., Tamás Sovány 
 Effect of Processing Conditions and Material Attributes on the Design 
 Space of Lysozyme Pellets Prepared by Extrusion/Spheronization 
15:30-15:45 Break 
15:45-17:30 Section 6. – Chair: Dr. Eva Šnejdrová, Dr. Szilvia Berkó 
OP-35 – 15:45-16:00  Tamás Kiss, Rita Ambrus 
 Treatment of the off-periods of Parkinson’s disease with levodopa and 
 its derivative 
OP-36 – 16:00-16:15  Luca Éva Uhljar, Rita Ambrus 
 Investigation of bottom-up prepared nanostructures 
OP-37 – 16:15-16:30  Reihaneh Manteghi, Gerda Szakonyi, Ildikó Csóka 
 PEGylation and formulation strategies of antimicrobial peptides and 
 proteins development 
OP-38 – 16:30-16:45  Mahwash Mukhtar, Rita Ambrus 
 Development of Inhalable Chitosan nano system conjugated with 
 Hyaluronic acid for treatment of Tuberculosis 
OP-39 – 16:45-17:00  Fakhara Sabir, Ildikó Csóka 
 Significance of QbD in design and development of coated liposomes for 
 nose to brain delivery 
OP-40 – 17:00-17:15  Krisztián Pamlényi, Katalin Kristó, Géza Regdon jr. 
 Development and characterization of sodium alginate polymer film as a 
 buccal mucoadhesive drug delivery system 
OP-41 – 17:15-17:30  Zorica Drinić, Senka Vidović 
 Influence of process parameters on supercritical carbon dioxide 
 extraction of cannabidiol from Cannabis sativa L. aerial parts 
17:30-17:45 Closing remarks 
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In vitro and ex vivo investigation of steroid containing ocular drug delivery 
systems 
Tivadar Bíró, Zoltán Aigner 
Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary 
 
The poor bioavailability in ocular drug delivery is well known, which is mostly caused by the 
special defensive mechanisms and complex anatomical structure of human eye. Possibilities 
are known for inducing enhanced therapeutic efficacy - due to increasing the solubility of drug 
and the residence time on the eye surface. Formulation specialists need to ensure not only 
the optimal drug permeation but also the required microbiological stability. The widely 
applied benzalkonium-chloride is toxic on the corneal epithelial cells, therefore use of 
alternative, nontoxic preservative agents is needed [1]. 
Cyclodextrin containing, mucoadhesive ocular drug delivery systems were optimized by our 
research group. Results of mucoadhesion, surface tension, viscosity, in vitro drug diffusion and 
antimicrobial effectiveness test were previously published [2]. Afterwards, in vitro toxicity and 
permeability were studied on human corneal epithelial cell line, and ex vivo drug permeability 
was tested using porcine corneal model. As the results show, toxicity and permeability are 
more suitable, than benzalkonium-chloride containing compositions or suspension forms. In 
summary, the prepared formulations could be innovative approaches for steroid containing 
eye drops with increased bioavailability. 
 
References 
1. Bíró T. Aigner Z. Sci. Pharm. 87, 15 (2019) 
2. Bíró T. et al. Drug Des. Dev. Ther. 12, 2529-2537 (2018) 
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This work was supported by the UNKP-19-3-SZTE-26 New National Excellence Program of the 
Ministry for Innovation and Technology 
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Spray vs freeze-dried solid lipid microparticles: Challenges in development 
Jelisaveta Ignjatović, Sandra Cvijić, Jelena Đuriš 
Department of Pharmaceutical Technology and Cosmetology, University of Belgrade-Faculty of Pharmacy, 
Belgrade, Serbia 
 
Lipid particles appeared as an alternative carrier to traditional polymeric microparticles and 
nanoparticles. Although lipid microparticles (LMs) can be delivered by common routes (oral, 
topical and parenteral), LMs can take advantage over other carriers due to their size, and be 
the most appropriate for specific administration routes (e.g. pulmonary) [1]. For the purpose 
of this study, QbD approach was applied in formulation and production of solid lipid 
microparticles (SLMs) using glyceryl dibehenate or stearyl alcohol. SLMs were prepared by 
melt emulsification method in conjunction with freeze or spray-drying, in order to obtain 
water-free particles. Ishikawa diagram was constructed to identify the parameters that could 
affect the quality of SLMs. SLMs size, morphology, density, drug content, dissolution rates and 
in vitro aerosol performance were evaluated for selected samples. Results have indicated that 
spray-dried SLMs had smaller particle size and higher drug content than freeze-dried SLMs. In 
addition, spray-dried samples were porous particles with lower true density (approximately 1 
g/cm3). Consequently, aerodynamic performance of several spray-dried samples was 
satisfactory since they exhibited fine particle fraction (FPF) > 20%, which is a respectable 
percentage for this type of formulations, where FPF values of 20-30% were usually observed. 
Dissolution studies showed that slower drug release can be achieved when glyceryl 
dibehenate was used regardless of the drying method.  
It can be concluded that spray-dried SLMs can be potential formulations for pulmonary drug 
delivery whereas freeze-dried SLMs are more suitable for other administration routes.  
 
References 
1. Scalia S, Young PM, Traini D. Expert Opin. Drug Deliv. 12(4), 583-599 (2015) 
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Formulation of nasal drug delivery systems to induce systemic and central 
nervous systemic effect 
Péter Gieszinger, Rita Ambrus, Piroska Szabó-Révész 
Institute of Pharmaceutical Technology and Regulatory Affairs, Interdisciplinary Excellence Centre, University of 
Szeged, Szeged, Hungary 
 
In the last decades the nose has become one of the most researched among the alternative 
drug administration routes. The reason of the considerable attention is, that due to its unique 
anatomical and physiological properties, local, systemic and direct Central Nerve System (CNS) 
effects can be available. In the case of those therapies (e.g. CNS diseases, brain tumors), where 
the point of attack is in the brain, nasal drug administration can improve the efficiency of the 
treatment [1]. Particle size decreasing into the nano range is an up-to-date and common way 
to modify the properties of drugs that can affect its bioavailability in a positive way [2]. The 
aim of this research is to formulate and develop nasal dosage forms for lamotrigine (LAM), 
that is a BCS II. antiepileptic drug and only available on the market in tablet form [3]. Since the 
beginning a nanosized LAM containing nasal powder has been produced, the process of 
sample preparation has been optimized and the samples were tested in vivo [4]. Also, a LAM 
containing nanocapsule (NC) formulation has been produced and investigated in vitro and in 
vivo. 
ACKNOWLEDGEMENT 
Ministry of Human Capacities, Hungary grant 20391-3/2018/FEKUSTRAT is acknowledged. 
References 
1. Fasiolo T. et al. L. Eur. J. Pharm. Sci. 113, 2-17 (2018) 
2. Zhi H. L. et al. Asian. J. Pharm. 10, 255-274 (2015) 
3. Serralheiro A. et al. Int. J. Pharm. 490, 39–46 (2015) 
4. Gieszinger P. et al. Drug Dev. Ind. Pharm. 44, 1622-1630 (2018) 
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Formulation of medicated nanoparticles based on branched PLGA 
Juraj Martiška, Eva Šnejdrová, Milan Dittrich 
Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec 
Kralove, Czech Republic 
 
Poly(lactic-co-glycolic acid) (PLGA) is currently the most widely used biomaterial for 
encapsulation and prolonged delivery of therapeutic drugs, proteins and antigens [1]. We 
introduce originally synthesized branched PLGA derivatives with lower molar mass, and star 
or comb architecture as promising biodegradable carriers for prolonged or targeted drug 
release systems [2]. These polyesters were used as starting materials for nanoparticles 
formulation by nanoprecipitation, and double-emulsion method. We successfully 
incorporated various molecules such as Terbinafine, Rifampicin, and Small interfering RNA 
(siRNA). Multiple parameters as particles size, polydispersity, zeta potential, encapsulation 
efficiency, and loading capacity were monitored. Morphology of the nanoparticles was 
studied by scanning electron microscope (SEM). The use of the polymers with tailored 
properties resulted in formulation of the nanoparticles with desired particle size, 
mucoadhesive properties, and prolonged drug release profile which we attribute to the 
gradual swelling and degradation of the polyester in an aqueous medium [3]. The 
hydrophobicity and the polyester concentration revealed the main impact on the 
nanoparticles size ranging from 100 to 600nm [4]. Examined polyesters are perspective, 
original, and suitable for further observation. 
 
References 
1. Han F. Y. et al. Front. Pharmacol. 7:185, (2016) 
2. Snejdrova E. et al. Acta Pharm. 70, 63-75 (2020) 
3. Dittrich M. et al. J. Pharm. Sci. 103, 3560-3566 (2014) 
4. Martiska J. et al. Pharm. Dev. Technol. 24(10), 1308-1316 (2019) 
 
Supervisor(s): Assoc. Prof. RNDr. Milan Dittrich, CSc; PharmDr. Eva Snejdrova, PhD. 
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PLA-based nanofibrous systems for the treatment of periodontal disease 
Attila Léber, Erzsébet Csányi, Mária Budai-Szűcs 
Institute of Pharmaceutical Technology and Regulatory Affair, Faculty of Pharmacy, University of Szeged 
 
The plaque-induced forms of periodontal diseases are the most prevalent chronic 
inflammatory conditions seen in humans worldwide. Not only does it cause tooth loss, but it 
is also independently associated with systemic chronic inflammatory diseases [1—2]. 
The aim of this study was to develop and characterize a PLA-based nanofibrous drug delivery 
system containing metronidazole for local periodontitis treatment. 
Delivery systems were characterized in the form of native fiber mats and compressed disks. 
Scanning electron microscopy, X-ray diffraction analysis, and different measurements were 
carried out regarding wettability, in vitro drug release, and antimicrobial effectiveness. 
Results of the X-ray diffraction analysis suggest that PLA has a semi-crystalline structure, while 
metronidazole is in a crystalline form among the fibers. SEM pictures indicate that fibers are 
not damaged during compression. Wettability measurements show that the penetration of an 
aqueous medium is much easier in the case of fiber disks than in fiber mats. In vitro drug 
diffusion measurements revealed that – in accordance with the wettability results – the fiber 
mats and disks show different drug release profiles: disks provide rapid (24 h) dissolution of 
metronidazole, while mats exhibit sustained (96 h) drug release. Results of the microbiological 
study suggest that disks could inhibit the growth of disease-inducing anaerobic bacteria for 
2—3 days. 
In conclusion, the produced delivery systems could supplement or be an alternative to 
subgingival mechanical debridement and contribute to an effective periodontitis treatment. 
 
References 
1. Leber A., Curr. Drug Deliver. 15(6), 887-897 (2018) 
2. Leber A., Pharmaceutics 11(3), 142 (2019) 
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Influence of experimental model, active substance and polymer type on 
mucoadhesive properties of buccal tablets 
Ivana Kurcubic, Jelena Đuriš 
Department of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy, University of Belgrade, 
Vojvode stepe 450, Belgrade, Serbia 
 
Mucoadhesiveness is influenced by the presence of different excipients and active substances 
that increase or decrease the interaction strength between polymer chains and mucosal 
surface. Mucoadhesive properties of buccal tablets were determined by measurement of the 
work of adhesion required to separate the test formulation from the mucosa-mimetic 
material: mucin disc or mucin dispersion (TA.XT plus texture analyzer equipped with 
thermostated mucoadhesive rig) [1]. The aim of the present study was to compare the 
usefulness of mucin disc and 10% mucin dispersion and to determine the influence of the 
mucoadhesive polymers (PEO, HPMC) as well as propranolol hydrochloride (PR) on the 
mucoadhesive properties of buccal tablets. Both mucosa-mimetic models enable 
determination of mucoadhesiveness, however, the lowest values of work of adhesion were 
obtained using mucin dispersion. By analyzing of placebo tablets using mucin disc revealed a 
statistically significant difference only between the F1P and F6P formulations. These are tablets 
that contain the highest PEO polymer content and the lowest HPMC polymer content, 
respectively. Incorporation of PR into PEO based tablets led to a slight decrease in 
mucoadhesiveness, whereas in the case of HPMC based tablets an increase in 
mucoadhesiveness was observed. The highest Wad was achieved with high concentration PEO 
(F1P) tablets. 
Mucin disc and mucin dispersion serve as suitable surrogates, however more measurements 
are necessary to obtain reliable results. Addition of PR led to increase in mucoadhesiveness in 
certain formulation, while the type of polymer didn't affect the mucoadhesive properties. 
References 
1. Andrews GP. Biomacromolecules. 10(9), 2427–2435 (2009) 
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QbD development of a liposomal co-formulation with Doxorubicin and 
Simvastatin for an enhanced antiproliferative effect on T47D-KBluc cell line  
Cristina Barbălată1, Alina Porfire1, Anca Cherfan2, Felicia Loghin2, Ioan Tomuță1 
1 Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, University of Medicine and 
Pharmacy “Iuliu Hațieganu”, Cluj-Napoca, Romania 




The aim of the research was to develop a liposomal co-formulation with doxorubicin (DOX) 
and simvastatin (SIM). DOX is known for its high toxicity and thus, its association with a 
compound that also presents antiproliferative properties, like SIM, was explored in order to 
obtain a synergic/ additive effect. 
The Quality by Design (QbD) concept was applied for liposomes development to get a better 
understanding of how the selected formulation factors and process parameters (PPs) can 
influence the quality attributes (QAs) of the liposomes. In accordance with this, risk 
assessment was performed and hence, three formulation factors and two PPs were selected 
to be studied in a screening experimental design. The results showed that all three formulation 
factors, namely phospholipids, DOX and SIM concentration, had a great influence on the 
liposomes QAs like encapsulated drug concentration and encapsulation efficiency (EE%). As 
regards the PPs, only the pH of the ammonium sulphate solution was pointed out to have a 
slight influence on DOX EE%. 
Considering the results from the screening study, the optimization process was performed by 
means of a design of experiments with the aim of obtaining a design space and an optimal 
formulation which fulfils all our requirements.  
The antiproliferative effects of the combined administration of SIM and DOX was studied on 
T47D-KBluc breast cancer cell line, indicating a strong inhibitory activity. 
In conclusion, the co-administration of DOX and SIM in a liposomal formulation is a promising 
solution to inhibit the proliferation of T47D-KBluc breast cancer cells.  
Acknowledgements: University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj-Napoca, 









II. Symposium of Young Researchers on Pharmaceutical Technology, 
Biotechnology and Regulatory Science 




Stearylamine-based nanoemulsion: preparation, characterization and 
physical stability investigation 
Merima Sirbubalo1, Amina Tucak1, Edina Vranić1, Andreas Zimmer2 
1University of Sarajevo, Faculty of Pharmacy, Department of Pharmaceutical Technology 
2University of Graz, Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology and 
Biopharmacy 
 
Oil-in-water cationic nanoemulsions (CNE) are fine dispersions consisting of an oil core (from 
natural or synthetic origin) stabilized by a single cationic lipid or a mixture with phospholipids, 
non-ionic surfactants, and/or PEG-lipids. CNEs are considered to be suitable and potential 
delivery system for nucleic acids in gene therapy field due to their positively charged surface 
which complex with negatively charged gene material through electrostatic interactions [1]. 
The aim of the present study was to evaluate the effect of cationic lipid-sterylamine (SA) on 
mean droplet size, zeta potential and pH of the CNEs. Formulations containing various 
concentrations of SA were prepared on high-pressure homogenizer. The mean droplet size 
and zeta potential of the emulsions were determined by photon correlation spectroscopy  and 
electrophoretic light scattering, respectively (Malvern NanoZs Zetasizer). The mean droplet 
size of emulsions varied from 126 to 129 nm while the polydispersity index varied from 0,068 
to 0,137. As expected, zeta-potential increased from +43,7 mV to +53,7 mV with the SA 
concentration increase from 0,25 to 0,75 % (w/w). During the 60-day storage period at 25 °C, 
the droplets stayed in the nanometer range with only a minor size increase (~10 nm), no 
significant changes in droplet size distribution nor zeta potential or any difference in their 
visual appearance (no creaming or phase separation) proving therefore a satisfactory 
formulation stability.   
 
References 
1. Teixeiraa H. et al. Int. J. Pharm. 534, 356-367 (2017)  
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Potential of polymeric and Lipid based nanocarriers for oral GLP-1 analogue 
delivery 
Ruba Ismail1,2, Ildikó Csóka 1,2 
1Institute of Pharmaceutical Technology and Regulatory Affairs, Institute of Pharmacy, University of Szeged, H-
6720 Szeged, Hungary. 
2Institute of Pharmaceutical Technology and Regulatory Affairs, Interdisciplinary Centre of Excellence, University 
of Szeged, H-6720 Szeged, Hungary 
 
Glucagon-like peptide-1 analogues, liraglutide (Lira) and exenatide (Exn), are currently limited 
to subcutaneous injections in clinical protocols [1].  Due to several drawbacks accompanied 
with this invasive route, the development of oral delivery system is likely the most attractive 
choice. Among the various strategies having been developed to conquer the barriers limiting 
oral peptide delivery [2], [3], the encapsulation of GLP-1 analogues into nanosystems seem to 
be very promising strategy. Herein, the aim is to discuss the potential of designing polymeric 
nanosystem and self-emulsifying drug delivery system (SEDDS) for oral delivery of Lira and 
Exn. Due to the complexity and nanotoxicological concerns of nanopharmaceuticals in 
addition to the risks entailed with peptides formulation development, it is critical to focus on 
quality by design (QbD) application when developing nanocarriers encapsulating peptide 
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Lactoferrin micro-encapsulation in Na-alginate hydrogel beads  
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Whey, co-product of milk processing was considered for years as a waste material and thus 
represented environmental burden. However, due to its protein rich composition, different 
scientific areas are oriented to the exploitation of whey potential. Lactoferrin (Lf) is an iron-
binding whey protein, which has antimicrobial, immunomodulatory, and antioxidant 
activities, thus expressing several beneficial effects on human health [1].     
The objective of the study was to develop and optimize composition of microcapsules with 
alginate and Lf, along with selection of appropriate microencapsulation parameters, drying 
process and conditions.   
Formulations with different alginate/ Lf ratios in water were prepared and subjected to 
microencapsulation by utilizing encapsulator Inotech IE-50 R in cross linking solution 
containing Ca2+ ions. Size distribution of dried microcapsules was evaluated through the image 
analysis and Lf content was determined by reverse phase HPLC.  
Obtained results revealed that by increasing Lf/ alginate ratio in initial dispersion (i.e. from 1:1 
to 2:1) size of microcapsules also increased, however by further increase of Lf/ alginate ratio 
to 4:1 no additional changes were observed. Moreover, due to the leakage of Lf from the core 
of the microcapsules, only a minor differences in Lf content were demonstrated.  
Our results suggest that by incorporation Lf in alginate dispersion microcapsules can be 
prepared and formulated in final dosage form for oral administration. However, by 
appropriate formulation composition and inclusion of additional excipients leaking of Lf has 
to be further investigated.  
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Curcumin loaded PEGylated nanoemulsions: development and 
physicochemical characterization towards in vivo pharmacokinetic 
experiments 
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PEGylated nanoemulsions (NEs) can increase target site concentration of the incorporated 
active by increasing circulation time of the oil droplets [1]. Using experimental design 
approach best preparation conditions were chosen for further research. Curcumin was used 
as a model drug and incorporated into formulations selected by experimental design. The aim 
of this study was to follow the stability of PEGylated and the non-PEGylated NEs and to assess 
the impact of PEGylated phospholipids’ (PEG-PLs) addition on nanoemulsions’ long term 
stability. Additionally, the impact of PEG-PLs on drug release was assessed through in vitro 
drug release studies in order to choose the best candidates for in vivo pharmacokinetic study. 
NEs were prepared by high pressure homogenization [2]. Nanoemulsions’ stability was 
followed for 12 months by measuring mean droplet size (Z-ave), polydispersity index (PDI) and 
zeta potential (ZP). Drug release was studied by reverse dialysis bag method. 
Initial Z-ave of all NEs (103–106 nm), PDI (< 0.2) and ZP around –40 mV, suggested they are 
adequate for parenteral application. After 12 months these parameters did not significantly 
change. During in vitro release study the biggest release of curcumin was from the formulation 
containing 0.3% of PEG5000DPPE (43.38%) vs the lowest with 0.1 % of PEG2000DSPE (25.88%). 
This study showed the usefulness of D-optimal factorial design in NEs development. 
Formulations containing 0.1 % of PEG2000DSPE/PEG5000DPPE were chosen for further step - 
a pharmacokinetic study. 
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Recently, nanosystems have been developed to improve drug properties and facilitate 
delivery. In practice, nanosystems contain particles within a particle size of less than 1000 nm. 
Loratadine (LOR) is a H1 antihistamine drug commonly prescribed for the treatment of allergic 
conditions. LOR has poor aqueous and pH-dependent solubility. Consequently, the oral 
administration is associated with variable and poor bioavailability. 
This study investigated the preparation of LOR nanosystems using top-down technologies, 
particularly precipitation and electrospraying. The critical process and material parameters 
have been identified and optimized in light of the required attributes. 
The two different approaches had different morphologies and physicochemical properties. 
Therefore, different solubility and dissolution rates. On the other hand, LOR showed an 
amorphous state in both systems [1].  
The nanosystems displayed a particle size of the range of 168-254 nm of LOR nanosuspensions 
and 372 nm diameter for the nanofibers. In the first 10 min, the nanosystems showed 
dissolution rates of 30–42% and 66% for the nanosuspensions and nanofibers, respectively 
[2–3]. 
The reduction of the particle size is associated with improved dissolution rate, thus 
bioavailability. Moreover, this improvement could enable the design of new alternative LOR 
formulations, including buccal, transdermal, and topical dosage forms. 
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Quality by Design (QbD) is a new perspective to replace the traditional, “in-process study”-
based quality control procedures of the Quality by Testing (QbT) method, which concept has 
been started to use in the pharmaceutical developments since the beginning of the 2000s. 
The objective of our research project was to conduct a QbD-based development process to 
prepare liposomal formulations and thus investigate the effects of various production 
parameters (filtration, pressure, and temperature) and different compositions (phospholipid-
cholesterol ratios, hydration media, and cryoprotectants). 
The liposomal formulations were prepared by the thin-film hydration method [1]. The 
temperature and the pressure during the production were changed in addition to the 
filtration, as well as the ratio of the wall-forming agents. The products were investigated via 
dynamic light scattering technique to determine the vesicle size and the size distribution, and 
the zeta potential values were checked. The thermostability of the samples was analysed via 
differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) measurements. 
N2 adsorption and desorption isotherms were measured to define the characteristics of the 
vesicular surface and the structure of the vesicles was verified via transmission electron 
microscopy (TEM). 
The size of the prepared vesicles was under 200 nm, and the zeta potential values were slightly 
negative, except the API-containing formulations. 
The results showed that the quality of the development process can be improved via the 
application of the QbD-based approach in the case of the liposomal formulations. 
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ultrasound and microwave assisted extraction: anti-hyperglycaemic activity 
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White horehound (Marrubium vulgare L.) is a grey-leaved perennial herb, belonging to 
Lamiaceae family, distributed in Eurasia and northern Africa zones [1]. According to the recent 
literature, horehound shows several in vivo and in vitro activities including antihypertensive, 
antioxidant, antiinflammatory, antidiabetic, effects on respiratory system, digestive stimulant, 
antiasthmatic, hypolipidemic, antibacterial and antifungal effects [2,3,4,5,6,7]. Having a scarce 
information about ultrasound assisted extraction (UAE) of horehound and several articles 
focusing on intensification of marrubiin content by microwave assisted extraction (MAE), the 
idea to compare these modern extraction techniques imposed. UAE and MAE were 
confronted in reference to extraction yield, polyphenols content, antioxidant potential and 
antidiabetic activity. Response surface methodology was used for optimization of process 
parameters in UAE and MAE. The optimal UAE parameters for maximized polyphenols and 
antioxidant activity were temperature of 73.6 °C, extraction time of 40 min and ultrasound 
power of 30.3 W/L, while in case of MAE the optimal parameters were 63.8% ethanol, 
extraction time of 15 min and microwave power of 422 W. The optimal UAE and MAE extracts 
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Development of QR coded tablets for anti-counterfeiting of drugs by laser 
technology 
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Counterfeit drugs pose a growing threat to our health as they can lead to hazardous treatment 
or even cause death. According to the WHO reports from 2017, the failure rate of these 
medical products is approximately 10.5% [1]. Drugs purchased on the Internet could be fake 
in 50% [2]. 
According to Directive 2011/62/EU to protect the pharmaceutical supply chain from 
substandard and falsified medicines, individual identification should be put on the packaging 
of prescription medicines. We are working on developing a unique traceable QR code placed 
on the surface of the tablet [3]. With this technology, even patients would be able to 
authenticate these drugs by a mobile phone with suitable application. 
Coated tablets were marked by different types of lasers (YAG laser, excimer laser, 
semiconductor laser). Analytical quality control was carried out on the tablets to check if there 
occurred any change during the laser coding, by SEM, Raman, Thermogravimetry and Mass 
spectrometry. 
It was found that some lasers with particular parameters are suitable for marking a unique 
code on tablets against counterfeiters, and others are not. Personalized medicines could also 
be labelled in this way. 
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Nanostructured lipid carriers for ophthalmic use 
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The development of ophthalmic formulations is a major challenge. The most commonly used 
ophthalmic formulations are eye drops which have low bioavailability due to the complex 
structure and the elimination mechanisms of the eye [1].  
Nanostructured lipid carrier (NLC) is the term used for the second-generation solid lipid 
nanoparticles that contain a lipid matrix of mixed solid and liquid lipids. These systems are 
ideal to incorporate low water-soluble active substances such as corticosteroids [2]. 
The aim of this work was to create a dexamethasone (DXM) loaded NLC formulation to 
increase the bioavailability of DXM, which is a lipophilic drug with poor solubility in water. As 
a preformulation study, lipid screening (visual observation, XRD, DSC measurements and 
investigation of blank NLCs) were applied to choose the most suitable excipients for the 
formulation of the system. A 23 factorial design was used to investigate the effects of the 
excipients on zeta potential, mean particle size, PDI and entrapment efficacy. The 
independent factors were lipid, DXM and surfactant concentration. Based on the one-month 
stability test, a lower surfactant and lipid concentration could be beneficial. The ophthalmic 
toxicity was investigated on human cornea cells and the results show that the measured NLC 
formulations have good ophthalmic tolerability. The in vitro drug release study suggests that 
the NLC formulations increase the diffused amount of DXM in the acceptor phase, while the 
penetration study on porcine cornea with Raman mapping predicted a higher amount of 
nanocarriers in the stroma layer.  
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Chitosan/xanthan polyelectrolyte complexes (PECs) are considered promising oral drug 
delivery carriers due to nontoxicity, biodegradability and can be investigated as potential 
carriers for extended drug release [1,2]. Ibuprofen has short half-life (t1/2~2 h) and requires 
frequent administration of immediate release dosage forms [3]. The aim of this study was to 
investigate the influence of the ibuprofen encapsulation procedure on its in vitro release 
kinetics. Dried PECs, prepared with chitosan solutions adjusted to pH 4.6 using acetic acid, and 
ibuprofen dispersed in the xanthan solution before (4.6B) or added after (4.6A) the 
complexation of polymer aqueous solutions, comprising 100 mg of ibuprofen, were filled into 
size 0 capsules. In vitro release profiles in the paddle apparatus (50 rpm) (Erweka DT70, 
Germany) were obtained using 900 ml of phosphate buffer pH 7.2 at 37 ± 1 °C. Both samples 
showed extended ibuprofen release during 12 h. From 4.6B 100% of ibuprofen was released 
after 12 h. From 4.6A 66.41 ± 2.14% of substance was released after the same time. Ibuprofen 
release from the samples followed the Korsmeyer-Peppas kinetics and the release mechanism 
was a combination of swelling, erosion and diffusion (0.5<n<1). PEC 4.6B showed better 
control of ibuprofen release and its preparation conditions are considered optimal for 
controlled extended drug release.  
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Ceramic materials such as titania are hydrophilic by nature due to the existence of hydroxyl 
groups, which limits their applications. Therefore, the hydrophobization process is needed in 
order to improve their permeability and other physicochemical properties besides decreasing 
their toxicity [1]. 
In the previous stage of the study composites of TNT with atenolol (ATN) and 
hydrochlorothiazide (HCT) were formed using various solvents [2]. The physicochemical 
properties of the samples were investigated by using TEM (FEI, OR, USA) and SEM (Hitachi, 
Japan) imaging to analyze the texture, an optical contact angle tester (DataPhysics, Germany) 
to determine the surface free energy, a FT-IR spectrometer (Thermo Fisher Scientific Ltd., MA, 
USA), and a DSC/TG apparatus (Mettler-Toledo Ltd, Hungary) to detect the interaction 
between drugs and TNTs. According to the results, the appropriate choice of the solvent leads 
to a better quality of the formed composite, which results in improved dissolution properties. 
However, the composite was found to be unable to be absorbed as drug delivery system. 
Therefore, TNTs were functionalized by using trichlorooctylsilane, trichloroocatdecylsilane 
and Mg stearate in order to improve their permeability and decrease toxicity. 
The characterization of functionalized TNTs was assessed by using TGA, OCA, CHNS elemental 
analyser and FT-IR. Toxicity was studied with MTT assays while the result of the permeability 
study was evaluated with an X-ray fluorescent analyser.   
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Fused deposition modelling (FDM), constitutes a versatile and cost-effective representative of 
the 3D-printing (3DP) techniques. With roots in engineering, it was first considered for 
pharmaceutical purposes based on its potential of personalization.  
Compared to the conventional powder compaction methodologies, in this case the tablet is 
constructed from melted and extruded subsequent layers. As, for the drug, it is incorporated 
within a filament, which for appropriate mixing and loading purposes, nowadays is 
manufactured via preliminary hot melt extrusion (HME). 
The integration of 3DP-FDM in pharmaceutics is promising. The technology is capable of 
producing a wide palette of designs that normally are hard to produce, like channelled, 
layered, compartmented tablets, associating one or several APIs and release profiles. It can 
also bring quality improvements compared to conventional dosage forms. Case study proved 
that high quality floating tablets can be obtained via HME+FDM [1]. 
Still, the adaptation of pharmaceutical polymeric blends to FDM can be difficult as the 
appropriate rheological and mechanical equilibrium for the filaments is hard to obtain [2]. 
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Pulmonary drug delivery represents a new alternative treatment way for both local and 
systemic diseases (where, in addition to its beneficial properties, one-tenth of the active 
ingredient is sufficient to achieve the required effect by oral administration [1]). To accomplish 
this, the international literature distinguishes between nebulizers, pressurized metered-dose 
inhalers, and dry powder inhalers (DPIs). The development of the latter can be considered a 
"hot topic" these days, due to a large number of formulation options available. A number of 
solid excipients are being tested for their effect on aerosolization [2], but not a lot of data are 
currently available on the aerosolization effect of organic solvents (OSs) used in DPI sample 
preparation [3]. Thus, the purpose of the present work was to investigate the effects of a given 
OS in different concentrations on powder properties and in vitro lung model results of DPI 
formulations, and to develop the microcomposites for pharmaceutical form prepared in the 
ideal percentage of OS using different DPI capsule types in stability test. The study showed 
that the percentage of the OS of our choice during spray drying production influences the 
physical properties of the samples and thus the aerosolization. As a result of the formulations 
development for pharmaceutical form made in the optimal percentage of the applied OS, 
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Biopharmaceuticals represent one of the crucial areas in the pharmacy and are widely used to 
treat several diseases. Protein molecules are typically unstable in aqueous media, thus 
lyophilisation is the method of choice to transform such formulations into solid state. Initially 
biopharmaceuticals were intended for intravenous administration, whereas current trends 
are oriented in development of protein formulations for subcutaneous administration, which 
is associated with many challenges [1]. 
The main aim was to evaluate the effect of bovine serum albumin (BSA) concentration on 
formulation viscosity, further on related to critical quality attributes of lyophilized 
formulations, such as reconstitution time and visual appearance.  
Formulations with five different BSA concentrations (5, 20, 50, 70 and 100 mg/mL) in 
phosphate buffer and sucrose or sucrose/mannitol as excipients were subjected to 
lyophilisation. Lyophilised products were evaluated for visual appearance, reconstitution time 
and particle size by dynamic light scattering. In addition, viscosity and thermal characteristics 
of pre-lyophilized solutions were determined. 
Obtained results revealed that by increasing BSA concentration the reconstitution time was 
prolonged, while cake appearance was improved. Independent of formulation composition, 
the particle diameter was below 9 nm indicating absence of aggregates. Furthermore, an 
increase of viscosity with increasing BSA concentration was demonstrated. 
The study indicates that BSA concentration along with excipient added have a decisive impact 
on lyophilized formulation characteristics, namely prolonged reconstitution time and 
increased viscosity both represent a main challenge in development of highly concentrated 
protein formulations. 
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Alzheimer's disease (AD) has been ranked as the most dangerous and prevalent 
neurodegenerative disease worldwide accompanied by the absence of a fully effective anti-
AD medication tightly due to the presence of the blood-brain barrier (BBB). Nose-to-Brain 
delivery enhances the ability of some drugs to bypass the BBB achieving a therapeutic 
concentration directly in the brain especially for those with low brain concentrations after a 
routine delivery. Since the inflammatory process is involved in the pathogenesis of AD and the 
association of meloxicam with antioxidant properties, the latter could be used in AD 
management. Unfortunately, poor permeability across the BBB limits its use for the treatment 
of neurodegenerative disorders in addition to the high rate of plasma protein binding and low 
apparent distribution volumes.  Encapsulation of meloxicam in lipid based nanocarriers, 
particularly solid lipid nanoparticles (SLN) could be promising for nose to brain delivery due to 
their biocompatibility, protecting the therapeutic load, while improving its interaction with 
the olfactory regions. 
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The purpose of this study was to prepare terbinafine hydrochloride (TER) solid binary systems 
with amorphous cyclodextrin derivatives (hydroxypropyl-β-cyclodextrin (HPBCD), 
heptakis(2,6-di-O-methyl)-β-cyclodextrin (DIMEB)) by co-grinding and perform analytical 
studies. Cyclodextrin–TER complexes were prepared in the 1:1 molar ratio. The products were 
investigated for both solid phase characterization (differential scanning calorimetry (DSC), X-
ray powder diffractometry (XRPD), hot-humidity stage X-ray powder diffractometry (HOT-
XRPD), Raman spectroscopy, Fourier transform infrared spectroscopy (FT-IR)) and dissolution 
properties (dissolution studies). DSC and XRPD studies indicated that with the increasing 
grinding time the crystallinity of products gradually decreased, and the products were 
completely amorphous after 75 minutes of grinding. HOT-XRPD studies were carried out in a 
wide temperature range and revealed that product containing HPBCD remained amorphous 
with the increasing temperature, while in the case of DIMEB the complex recrystallized in a 
different crystalline phase. Raman and FT-IR spectroscopy were used to investigate the 
molecular interactions between the components. Both products presented a notable 
improvement in its dissolution rate, and the solubility of TER increased both in simulated 
gastric and intestinal fluid, depending on the dissolution medium. Co-grinding is a solvent-free 
method to prepare stable amorphous cyclodextrin complexes and improve solubility and 
dissolution ratio. This could cause enhanced biopharmaceutical properties of the active 
ingredients in solid pharmaceutical products. 
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Cationic NLCs represent lipid vesicles bearing cationic lipids on its surface, which leads to 
electrostatic interactions with negative charges of the nucleic acids such as miRNA and 
formation of a complex which protect the nucleic acids from the inevitable physicochemical 
biological impacts within the blood circulation [1]. This study aimed to develop cNLCs in order 
to obtain the most suitable formulation for further delivery of miRNAs.  
cNLCs containing stearylamine, Precirol® ATO 5 and Miglyol® 812 in the lipid phase and 
different concentrations of Poloxamer® 188 and Tween® 80 in the aqueous phase were 
prepared by the high-pressure homogenization method. In order to evaluate appropriate 
process parameters for NLC preparation, different cycle numbers (1-5) and homogenization 
pressures (500 bar, 650 bar and 800 bar) were tested. Additionally, the influence of the cooling 
technique was investigated. cNLCs were characterized regarding particle size, particle size 
distribution, zeta potential, and crystallinity using photon correlation spectroscopy technique 
and laser diffraction, electrophoretic light scattering, and differential scanning calorimetry, 
respectively.  
The obtained particle size of all formulations was between 80 and 180 nm, and it decreased 
significantly with the increase of non-ionic surfactant concentration. Furthermore, particle 
size decreased with the increase of the homogenization cycles. The surface charge value was 
highly positive in formulations (+32 to +41 mV), demonstrating the successful incorporation 
of stearylamine onto the nanoparticle surface. However, the cooling technique did not have a 
significant impact on the particle size of cNLCs. 
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Fused Deposition Modeling Three-Dimensional Printing (FDM-3DP) of 
Channelled Tablets with Ketoprofen: Design, Development and 
Pharmaceutical Evaluation 
Andrea-Gabriela Crișan, Ioan Tomuță 
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Pharmacy „Iuliu Hațieganu”, Cluj-Napoca, Romania 
 
Three dimensional printing (3DP) constitutes an innovative approach in the pharmaceutical 
field with promising potential for the production of personalized medicine, among the 
available techniques Fused Deposition Modeling (FDM) representing a flexible, simple and 
cost-effective alternative. The aim of the present study was obtaining and evaluating a 
channelled tablet model produced by FDM-3DP, using custom made pharmaceutical polymer-
based filaments. 
Ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID) was selected as the model active 
pharmaceutical ingredient (API), while polyvinyl alcohol (PVA) represented the matrix forming 
polymer with thermoplastic behaviour in which the API was included. Feedstock filaments 
were obtained by hot melt extrusion (HME), followed by FDM-3DP of the tablets. Assessment 
of the final product included pharmacotechnical characterization and in vitro dissolution 
studies. 
Results demonstrated the feasibility of higher drug loaded, printable filaments. Plasticization 
was achieved by elevated API content, generating custom made filaments with proper 
mechanical and rheological properties. In vitro dissolution testing revealed a complete release 
of the drug up to 4h. Humidity was identified as a factor which could impact the quality of the 
dosage form, subsequently preventive measures are required during preparation and storage. 
Production of pharmaceutical dosage forms by a bi-phase technique such as FDM- coupled 
with HME creates opportunities to improve safety, efficacy and accessibility of medications. 
FDM-3DP is a versatile tool which could be developed as a single platform qualified to adapt 
dosage forms based on patients’ needs, preferences or individual features. 
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Powder Compressibility Assessment: Manufacturability Classification System 
vs. SeDeM Expert System 
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Manufacturability Classification System (MCS) and SeDeM Expert System have been proposed 
as mathematical tools facilitating directly compressible tablet formulation [1, 2]. The aim of 
this work was comparative evaluation of SeDeM and MCS for powder compressibility 
assessment. 
Three active ingredients (ibuprofen, caffeine, paracetamol) and four directly compressible 
excipients (Ludiflash, Disintequik ODT, Pharmaburst 500, Parteck M200) were evaluated. The 
investigated powders were characterized with respect to relevant properties determining 
their flowability and compression behaviour. Experimentally obtained data were 
mathematically transformed to radii parameters for further evaluation. Subsequently, 
parameter profile (IPP) and good compression indices (IGC) were calculated as representative 
measures for powder compressibility assessment. 
The results obtained revealed high level of correlation between the IPP and IGC values 
estimated using both investigated approaches, characterized with the correlation coefficient 
of 0.9266. While SeDeM expert system is less demanding with respect to the experimental 
setting required and includes somewhat simpler mathematical processing of the experimental 
data, MCS provides more detailed insight into material properties influencing powder 
compression. Furthermore, discriminatory power of the MCS approach appears to be higher 
since it was able to clearly differentiate poorly performing paracetamol and ibuprofen from 
caffeine and directly compressible/co-processed excipients (i.e. 3.9 and 6.4 vs. approx. 8.5). 
Data obtained can be employed as a proof of concept for further elucidation of flowability and 
compression behavior of more complex, composite powder samples and multiparticulates. 
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The batch-wise wet granulation, drying and tableting are ones of the most widely used 
technologies in the pharmaceutical industry, with potential impact on both product quality 
and processability in subsequent steps.  
Multivariate data analysis by means of Principal Component Analysis and Projection to Latent 
Structures models can cope with the highly inter-correlated variables of interest from these 
processes.  
In this study, the multivariate modelling approach was challenged using a historical dataset 
from 95 industrial-scale batches.  This increases the level on inter-correlation even more as 
the available data are not the result of a planned study. 
Batch level models show a good correlation between raw material properties and the 
evolution of torque values during wet granulation, with 70 % of the Y-variability explained by 
the model and showing a decent predictability (Q2 = 0,7). The evolution of torque values 
during wet granulation and the raw material properties are correlated with differences 
observed in the granulate particle size and disintegration time of core tablets. 
Expected correlations were confirmed by this modelling exercise (eg. the influence of active 
product ingredient particle size), but also new insights were gained regarding the influence of 
different excipient batches. Despite the relatively tight specification ranges applicable for 
excipients, the multivariate influence of all raw materials is a good starting point to consider 
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API – excipient interactions in solid matrix systems 
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Solid dosage forms are still the most preferred types of medicines in the pharmaceutical 
market. Due to the emerging trend on personalized medicine, the pharmaceutical industry 
faces a new challenge on providing matrix systems with tailorable properties. To fulfil this 
request, a novel approach of pharmaceutical design may be applied with a more detailed 
investigation of physico-chemical property-based interactions between the drug and the 
applied excipients. The main aim of this research work is the better understanding of these 
interactions and fulfilling the requirements of the ‘Functionality related properties of 
materials’ concept of Quality by Design. 
A line of chemically similar APIs and matrix forming agents were mixed and directly 
compressed with an instrumented IMA Kilian SP300 tablet press. The interactions formed 
within the tablets were studied by FT-IR and NIR spectroscopy, and a custom-made device was 
used to perform dissolution tests to obtain information about the effects of interactions on 
the drug liberation kinetics. 
The spectral information revealed that hydrogen bonds are formed between the drug and 
excipients even in solid state, while investigations during dissolution tests proved that the 
strength of interactions increased due to the formation of polyelectrolyte complexes, which 
affects not just the speed of drug liberation but also the quantity of the liberated drug. 
According to the findings it can be concluded that in addition to the physico-chemical 
properties of the drug delivery system, drug liberation is considerably influenced by the 
chemical interactions formed between APIs and excipients.  
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Study of Skin Penetration Testing Methods 
Stella Zsikó, Erzsébet Csányi, Szilvia Berkó 
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Modeling of penetration through the skin is a complex challenge. The success of topical and 
transdermal therapy is correlated to the techniques used for the evaluation of the 
preparations, which facilitate the optimization of the skin penetration of the API. Human skin 
tests give the most relevant information; however, because of the high cost, it is a generally 
accepted approach to choose simpler methods in the early stages of formulation 
development. In my PhD work, I study different in vitro tests which are used and reliable tool 
for evaluating products [1, 2]. Although there are many methods for following up skin 
penetration/permeation the different techniques are not fully equivalent but complement 
each other. Different types of vertical Franz diffusion cells, the Skin-PAMPA method and 
Raman mapping have been compared. The models can make rapid screening and faster 
optimization possible especially in the early stage of development. The selection of the most 
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Nano-crystalline suspensions of novel pyrazoloquinolinones ligand (DK-I-56-1): 
physicochemical and in vivo pharmacokinetic and behavioural characterization 
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Very low solubility in water and oils (<10 µg/ml) of DK-I-56-1 (7-methoxy-2-(4-methoxy-d3-
phenyl)-2,5-dihydro-3H-pyrazolo[4,3-c]quinolin-3-one), the new drug candidate from the 
group of deuterated pyrazoloquinolinones [1], was the reason for investigation of nano-
crystalline suspensions (nanosuspensions) as prospective carriers. Nanosuspensions are 
dispersions of nanocrystals with submicron size stabilized by different surfactants and/or 
polymeric stabilizers [2]. In this research, formulation and comprehensive characterisation of 
DK-I-56-1 nanosuspensions were carried out. Nanosuspensions stabilized by polysorbate 80 
alone or in combination with poloxamer 188, poloxamer 407 or d-α-Tocopheryl polyethylene 
glycol 1000 succinate were prepared by small scale media milling technique. All formulations 
had particle size 208.7 – 250.6 nm, polydispersity index <0.250 and zeta potential around -20 
mV, and were stable for three weeks. According to thermal and X-ray diffraction analysis DK-
I-56-1 remained in crystalline state in all samples. Results from biodistribution studies in mice 
after intraperitoneal administration showed high plasma DK-I-56-1 levels after 
nanosuspension administration (AUC values for nanosuspension, suspension and solution: 
6770.35±770.69; 966.01±58.10; 10228.58±1037.23 ngh/ml, respectively). Brain availability 
was higher after nanosuspension compared to solution, while concentration profile after 
suspension showed bimodal characteristics. In in vivo behavioural (spontaneous locomotor 
activity) tests hyperlocomotion was observed after nanosuspension administration compared 
to saline or placebo (F(2,31)=7.126, p<0.01), while placebo was not behaviourally active 
compared to saline (p=0.289). In conclusion, DK-I-56-1 nanosuspensions with short term 
stability could be prepared and should be investigated as promising carrier for preclinical 
investigation.   
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Formulation and investigations of lysozyme nanoparticle 
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Lysozyme is an alkaline enzyme found mostly in plants, animals, and microbes. It can damage 
bacterial cell walls by catalysing the hydrolysis of 1,4-b-linkages between muramic acid and N-
acetyl glucosamine in mucopolysaccharides and is present in various human tissues and 
secretions. Therefore, it is widely used as a cell-disrupting and potent anti-bacterial reagent. 
It is also in high demand due to its unique pharmacological functions such as anti-
inflammatory, antiviral, antiseptic, and antineoplastic activities [1]. It is naturally occurring, 
non-toxic, and easy to digest and absorb. 
Nanoparticles can change and improve the properties of proteins such as mechanical, 
degradable properties and they can protect and control release of the bioactive substances as 
a delivery system [2]. 
For the purpose of this research, we carried out pre-formulation experiments by varying 
factors such as the concentration of the lysozyme and precipitating agent and the pH by using 
the factorial design method. Based on these variations, different formulations of the lysozyme 
and precipitating agent were prepared, tested and optimised and the resulting nanoparticles 
were comprehensively characterised. 
Furthermore, Statistica analysis measurements were carried out using the different values for 
the lysozyme concentration and the sodium sulphate amounts which served as determinant 
factors for the particle size of the lysozyme nanoparticle solution. 
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Low-energy nanoemulsions for curcumin delivery: investigation of the 
interfacial phenomena in the colloidal system and peculiarities important for 
biological performances 
Ines Nikolić, Snežana Savić 
Department of Pharmaceutical Technology and Cosmetology, University of Belgrade - Faculty of Pharmacy, 
Belgrade, Serbia 
Low-energy nanoemulsions (LE-NEs) represent novel and multifunctional drug carriers [1]. 
Curcumin, a powerful pleiotropic molecule, was used as a model active ingredient in this 
study. However, due to physicochemical instability, poor solubility and low targeting efficacy, 
its potentials are still beyond the reach [2]. Therefore, the aim was to investigate developed 
LE-NEs as promising vehicles for curcumin delivery, linking microstructural properties of the 
carrier to delivery and biological performance. 
After structural investigation, applying several physicochemical techniques (photon 
correlation spectroscopy, differential scanning calorimetry, atomic force microscopy, electron 
paramagnetic resonance spectroscopy), efficacy of curcumin and curcumin-loaded LE-NEs was 
assessed in terms of antioxidant activity and in biological assays with several cell lines (Fem-
X, HeLa, MRC-5). 
All developed formulations had mean droplet diameter below 150nm, with narrow 
distribution. It was demonstrated that curcumin interacts with the interfacial region of the LE-
NE, being a part of the surfactant layer, closer to the lipophilic region. Scavenging activity of 
curcumin-loaded LE-NEs was high, remaining unaltered after several months of storage. 
Encapsulation in the LE-NE enhanced its safety profile, providing significant cytotoxicity 
towards HeLa and Fem-X compared to the effect towards MRC-5 (IC50=22.89±2.09; 
37.87±7.09 and 67.72±0.4µg/ml, respectively). After the cell cycle analysis, it was proved that 
the cycle arrest of the cancer cells mostly happened in the subG1 and G2/M phase, underlining 
the ability of curcumin to interact with numerous cellular signaling pathways. 
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Investigation of semi-solid in situ film-forming systems with QbD approach 
Nikolett Kis, Szilvia Berkó, Erzsébet Csányi 
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The development of dermal preparations is a great challenge to provide good penetration 
through the skin because of the barrier function of stratum corneum. Film forming systems 
(FFSs) are new alternative drug delivery systems which can increase the impact of dermal 
preparations.  
The aim of my research work was to develop dermally applicable semi-solid in situ FFSs 
containing silicones, which form a film on the skin, with appropriate mechanical properties 
Silicones were used in the systems because of their “silky-touch” and protective effects to 
improve the quality of FFSs. FFSs were developed and investigated using the Quality by Design 
(QbD) approach. During the initial risk assessment, critical attributes were distinguished and 
measured. These critical quality attributes (CQAs) were skin adhesion, film flexibility and burst 
strength, film appearance, film integrity and the drying time of the semi-solid system. Critical 
material parameters (CMAs), namely the type of silicones, film forming excipients, drying 
excipients, and viscosity enhancing excipients were also found. 
The results showed that the silicone content had a great effect on the FFSs. They had an 
influence on the mechanical properties of the films, and on the drying time. The investigation 
of the drying mechanism showed promising results because of the silicon content. 
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Effect of Processing Conditions and Material Attributes on the Design Space of 
Lysozyme Pellets Prepared by Extrusion/Spheronization  
Yousif Ibrahim, Katalin Kristó, Géza Regdon jr., Tamás Sovány  
 
University of Szeged, Institute of Pharmaceutical Technology and Regulatory Affairs, Eötvös u. 6., H-6720, Szeged, 
Hungary 
 
The formulation of macromolecular drugs such as proteins into stable solid dosages 
represents a challenging goal as a result of the mechanical attrition and thermal stress 
involved during their production [1].  
This study aimed to investigate the impact of the material attributes and processing 
parameters on the quality of the prepared pellets containing a macromolecular drug. Spray-
dried and lyophilized lysozymes were used as a model protein, crystalline and spray-dried 
mannitol were involved as conformation stabilizers [2] and microcrystalline cellulose served 
as pellet former. The experiments were conducted according to 23 full factorial design. 
Kneading was performed in the high shear granulator equipped with seven temperature and 
relative humidity (RH) sensors (Opulus, Hungary). The obtained granules were extruded at 
different rates, and the extrudates were spheronized at a fixed rate.  
The dried samples were investigated for the enzyme activity and physical properties. It was 
found the material attributes have a potential effect on biological activity and pellet 
properties, as they demonstrated different thermal responses upon the applied mechanical 
stresses; lysozyme showed considerably good stability towards the applied mechanical stress 
and generated heat. It was concluded that the instrumented chamber represents a novel 
means for the online monitoring of temperature and RH%. Besides, screening of the 




1. Kristó et al., Eur. J. Pharm. Sci. 95, 62–71 (2016) 
2. Sovány et al., Chem. Eng. Res. Des. 106, 92–100 (2016) 
 





II. Symposium of Young Researchers on Pharmaceutical Technology, 
Biotechnology and Regulatory Science 




Treatment of the off-periods of Parkinson’s disease with levodopa and its 
derivative 
Tamás Kiss, Rita Ambrus 
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Levodopa is the gold standard API for the treatment of Parkinson’s disease. It is mainly 
administrated per os and absorbed in the small intestines. The bioavailability of the levodopa 
is low and alternates because of numerous disadvantages belonging to this route, for example 
fluctuating gastric akinesia, high first-pass effect. When the levodopa concentration is low, the 
symptoms of off-periods appear. The intranasal route is an alternative possibility to treat the 
off-periods [1]. 
Unlike the levodopa, the melevodopa can be absorbed in the stomach because it exists in the 
non-ionized form at low pH, additionally, its solubility is much higher, therefore the 
bioavailability can become higher. As it can be absorbed in the stomach, the onset can be 
increased and the gastric akinesia can be eliminated. 
The Syloid XDP 3050 –mesoporous silica – can adsorb a remarkable amount of compounds 
and the dissolution properties of the APIs can be regulated. 
During work, preliminary experiments were executed to prepare drug delivery systems with 
fast dissolution. In the first part of the study, levodopa-containing nasal powder formulations 
were prepared with co-milling using excipient. In this study melevodopa was adsorbed on the 
surface of the Syloid to prepare tablet formulations to achieve a fast dissolution in the gastric 
medium. Physicochemical and in vitro studies were performed with the products.  
Summarizing, drug delivery systems for the treatment of the off-periods of Parkinson’s disease 
were prepared. A comparison of the pharmacokinetic parameters of the formulations is 
planned. 
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Investigation of bottom-up prepared nanostructures 
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Generally, by systemic administration the low oral bioavailability can be caused by poor 
solubility. Therefore, increasing the water solubility of active pharmaceutical ingredients (API) 
enhances the oral bioavailability of drugs. Various nanonization techniques can be used to 
achieve increased solubility. Nanofabrication can be classified as bottom-up and top-down 
methods. The bottom-up strategy is considered more advantageous than the top-down 
approach because it has a better chance of producing more homogenous nanostructures. 
Electrospun nanofibers and nanocapsules could be examples of the bottom-up approach. 
Nanofibers can be prepared by using electric force during the electrospinning procedure. The 
amorphous form and the large surface area prove the increased water solubility of the API [1-
2]. Nanocapsules are vesicular systems that carry the API inside a cavity surrounded by a 
polymeric membrane. The advantages of the nanocapsules are reducing the toxicity and 
improving the stability of the drugs and the high drug encapsulation efficiency. 
Our aim is enhancing the water solubility and the dissolution rate of different APIs by bottom-
up nanofabrication methods such as electrospinning and nanoprecipitation. As a plan, the 
investigation of the prepared electrospun nanofibers and the nanocapsules covers the 
micrometric and physicochemical properties, in vitro dissolution of the API. The final purpose 
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The potential of antimicrobial peptide and protein agents has yet to be concerned owing to 
the many unresolved problems including low bioavailability, high manufacturing cost and 
toxicity concerning their delivery to the target site [1]. 
Novel chemical modification approaches as well as strategies for delivery of proteins and 
peptides offer several opportunities to overcome these barriers. However, these approaches 
hide several risks. This study presents a Quality by Design (QbD) based peptide and protein 
modification and formulation design. Analyses the potential risks in the peptide PEGylation 
process through the example of PGLa and on the other hand, the effective delivery of proteins 
with antimicrobial activity was accomplished through the example of lysozyme in a novel 
formulation strategy as layer-by-layer polyelectrolyte core-shell nanoparticle [2]. The 
precipitation method was applied for the formulation of core and the second step was the 
layering of polymers according to the factorial design. The particle size, zeta potential and 
enzyme activity were the optimization parameters. 
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Tuberculosis is the global health burden and the conventional therapies are unable to deliver 
the drug to the alveolar macrophages, where the causative agent (Mycobacterium 
tuberculosis) resides and replicates. The potential of chitosan polymer conjugated with 
hyaluronic acid was exploited for the targeted drug delivery via inhalation [1]. Nano mediated 
drug delivery vehicle was synthesized using ionic gelation for the active targeting of the 
alveolar macrophages. Dry powder inhalers (DPI) comprised of biodegradable polymeric 
nanocarriers with adequate aerodynamic profile, drug release and biocompatibility is a major 
challenge for pulmonary drug delivery. Quality by design approach was therefore employed 
to critically evaluate the risk assessment profile to enhance the product optimization [2]. 
Physicochemical tests including FT-IR, DSC, TGA, XRPD, SEM, size analyses and aerodynamic 
characterization provided useful data about compatibility and stability of the nanoparticular 
system. Nano DPI might hence improve the drug bioavailability by the reduction in dosing 
frequency and toxicity [3]. 
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Nose to brain delivery is noninvasive, direct and more effective route of administration than 
other invasive treatments that comes with many pitfalls. In this study quality by design (QbD) 
and risk assessment (RA) strategy was used for development of novel optimized liposomes 
encapsulated with propyl gallate (PG) for nose to brain delivery. This risk focused research 
helps to define target product profile, critical quality and process parameters were also 
analysed. The application of QbD helped in the box behnken design-based liposome 
preparation by the novel direct pouring method (DPM). Compatibility studies (FTIR, DSC, 
XRPD, TGA) were performed for materials used and for lyophilized optimized formulations. 
The prepared optimized liposomal preparations were characterized (particle size, 
polydispersity index, and surface charge). The surface morphology was also evaluated to 
confirm the precision of the RA and critical parameters based on QbD prediction. The following 
study verify that  in formulation of liposomes the RA startegy has significant importance. The 
developed optimized formulation via this novel approach results in maximum encapslation 
efficiency and minimum particle size. The implimentation of this novel QbD deisgn and models 
can assists in, to develop the rationalize liposomal formulation for nose to brain delivery. 
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Nowadays oral mucoadhesive systems have an increasingly greater role in the pharmaceutical 
industry. These systems can avoid the first-pass effect because they allow drugs to be 
absorbed directly into the systemic circulation and they have further advantages [1, 2]. The 
aim of this work is to formulate and evaluate polymer films of different composition that are 
able to bind to the buccal mucosa. 
Sodium alginate and hydroxypropyl methylcellulose (HPMC) were used as polymer, glycerol 
was the plasticizer, and cetirizine dihydrochloride served as active pharmaceutical ingredient. 
Mucin was used in the mucoadhesion tests. The polymer film was prepared at room 
temperature by solvent casting method. The polymer films contained different amounts of 
sodium alginate, HPMC and glycerol, but the same amount of cetirizine dihydrochloride. The 
thickness of the films was examined with a screw thread micrometer (Mitutoyo, Japan), the 
tensile strength and mucoadhesive force was tested with a laboratory constructed device.  The 
physical and chemical properties of the films were investigated with FT-IR (Avatar 330 
ThermoScientific, USA) and thermal analysis (Mettler Toledo, Switzerland). Surface free 
energy was examined by an optical contact angle-measuring apparatus (OCA20, DataPhysics, 
Germany). The dissolution of the active substance was tested by an ErwekaDT700 dissolution 
tester and the sample was measured by a UV spectrometer. The results showed that the 
material exerts a remarkable effect on the properties of polymer films, and the active 
substance showed homogeneous distribution. 
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Hemp (Cannabis Sativa L.) has multiple applications in the industry for the production of 
fabrics, paper and construction materials. Today, there is an increasing interest in its 
application for medical purposes, as opposed to its opiate activity. Hemp has more than 480 
compounds: cannabinoids, terpenoids, flavonoids, noncannabinoid phenols, hydrocarbons, 
nitrogen-containing compounds, carbohydrates [1]. 
The influence of pressure (100 - 300 bar) and temperature (40 ⁰C - 60 ⁰C) on supercritical 
carbon dioxide extraction of aerial parts of hemp in terms of cannabidiol (CBD) was examined. 
The CBD content was in the range from 0.0071 to 0.0896 g/extract for the pressure of 100 bar, 
from 0.1341 to 0.2587 g/extract for the pressure of 200 bara and from 0.1797 to 0.3103 
g/extract for the pressure of 300 bar. Depending on the pressure used, the temperature had 
a different effect. At the pressure of 100 bar increasing the temperature leads to decrease in 
the extraction of CBD. At pressures of 200 and 300 bar increasing the temperature to 50 °C 
amount of extracted CBD decreased, while further increasing the temperature to 60 °C 
amount of extracted CBD results in a slight increase. The highest content of CBD was in the 
extract obtained at a pressure of 300 bar and temperature of 40 °C. 
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